FactSet Research Systems Inc.
NYSE

REAL TIME PRICE

EXTENDED HOURS
Day’s Range -
52 Week Range -
Computer Programming, Dat...

Wolfe Research Initiates Coverage of FactSet Research Systems (FDS) with Underperform Recommendation

2024-04-12 05:39
US

Fintel reports that on April 11, 2024, Wolfe Research initiated coverage of FactSet Research Systems (NYSE:FDS) with a Underperform recommendation.

Analyst Price Forecast Suggests 9.48% Upside

As of March 31, 2024, the average one-year price target for FactSet Research Systems is 467.79. The forecasts range from a low of 375.72 to a high of $525.00. The average price target represents an increase of 9.48% from its latest reported closing price of 427.27.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for FactSet Research Systems is 2,272MM, an increase of 5.49%. The projected annual non-GAAP EPS is 16.54.

FactSet Research Systems Declares $0.98 Dividend

On February 2, 2024 the company declared a regular quarterly dividend of $0.98 per share ($3.92 annualized). Shareholders of record as of February 29, 2024 received the payment on March 21, 2024. Previously, the company paid $0.98 per share.

At the current share price of $427.27 / share, the stock's dividend yield is 0.92%.

Looking back five years and taking a sample every week, the average dividend yield has been 0.92%, the lowest has been 0.68%, and the highest has been 1.41%. The standard deviation of yields is 0.11 (n=234).

The current dividend yield is 0.05 standard deviations below the historical average.

Additionally, the company's dividend payout ratio is 0.31. The payout ratio tells us how much of a company's income is paid out in dividends. A payout ratio of one (1.0) means 100% of the company's income is paid in a dividend. A payout ratio greater than one means the company is dipping into savings in order to maintain its dividend - not a healthy situation. Companies with few growth prospects are expected to pay out most of their income in dividends, which typically means a payout ratio between 0.5 and 1.0. Companies with good growth prospects are expected to retain some earnings in order to invest in those growth prospects, which translates to a payout ratio of zero to 0.5.

The company's 3-Year dividend growth rate is 0.27%, demonstrating that it has increased its dividend over time.

What is the Fund Sentiment?

There are 1457 funds or institutions reporting positions in FactSet Research Systems. This is an increase of 10 owner(s) or 0.69% in the last quarter. Average portfolio weight of all funds dedicated to FDS is 0.25%, a decrease of 5.91%. Total shares owned by institutions increased in the last three months by 0.47% to 41,720K shares. FDS / FactSet Research Systems Inc. Put/Call Ratios The put/call ratio of FDS is 0.48, indicating a bullish outlook.

What are Other Shareholders Doing?

FDS / FactSet Research Systems Inc. Shares Held by Institutions

Bamco holds 2,778K shares representing 7.29% ownership of the company. In it's prior filing, the firm reported owning 2,752K shares, representing an increase of 0.94%. The firm increased its portfolio allocation in FDS by 0.94% over the last quarter.

Loomis Sayles & Co L P holds 1,596K shares representing 4.19% ownership of the company. In it's prior filing, the firm reported owning 1,612K shares, representing a decrease of 1.01%. The firm decreased its portfolio allocation in FDS by 47.41% over the last quarter.

Wells Fargo holds 1,505K shares representing 3.95% ownership of the company. In it's prior filing, the firm reported owning 1,517K shares, representing a decrease of 0.83%. The firm decreased its portfolio allocation in FDS by 3.66% over the last quarter.

BGRFX - BARON GROWTH FUND holds 1,200K shares representing 3.15% ownership of the company. No change in the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,191K shares representing 3.12% ownership of the company. In it's prior filing, the firm reported owning 1,185K shares, representing an increase of 0.49%. The firm decreased its portfolio allocation in FDS by 2.03% over the last quarter.

Factset Research Systems Background Information
(This description is provided by the company.)

FactSet Research Systems Inc. delivers superior content, analytics, and flexible technology to help more than 138,000 users see and seize opportunity sooner. the company gives investment professionals the edge to outperform with informed insights, workflow solutions across the portfolio lifecycle, and industry-leading support from dedicated specialists. FactSet is proud to have been recognized with multiple awards for our analytical and data-driven solutions and repeatedly scored 100 by the Human Rights Campaign® Corporate Equality Index for our LGBTQ+ inclusive policies and practices.

Stories by George Maybach

BMO Capital Downgrades MacroGenics (MGNX)
Fintel reports that on May 10, 2024, BMO Capital downgraded their outlook for MacroGenics (NasdaqGS:MGNX) from Outperform to Market Perform.

B of A Securities Upgrades Novavax (NVAX)
Fintel reports that on May 10, 2024, B of A Securities upgraded their outlook for Novavax (NasdaqGS:NVAX) from Underperform to Neutral.

CLSA Upgrades Bilibili Inc. - Depositary Receipt () (BILI)
Fintel reports that on May 10, 2024, CLSA upgraded their outlook for Bilibili Inc.

JonesTrading Initiates Coverage of TriSalus Life Sciences (TLSI) with Buy Recommendation
Fintel reports that on May 10, 2024, JonesTrading initiated coverage of TriSalus Life Sciences (NasdaqGM:TLSI) with a Buy recommendation.

MoffettNathanson Upgrades Roblox (RBLX)
Fintel reports that on May 10, 2024, MoffettNathanson upgraded their outlook for Roblox (NYSE:RBLX) from Sell to Neutral.

William Blair Downgrades Ginkgo Bioworks Holdings (DNA)
Fintel reports that on May 10, 2024, William Blair downgraded their outlook for Ginkgo Bioworks Holdings (NYSE:DNA) from Market Perform to Underperform.

Needham Downgrades Collegium Pharmaceutical (COLL)
Fintel reports that on May 10, 2024, Needham downgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from Buy to Hold.

Lake Street Downgrades Evolv Technologies Holdings (EVLV)
Fintel reports that on May 10, 2024, Lake Street downgraded their outlook for Evolv Technologies Holdings (NasdaqCM:EVLV) from Buy to Hold.

Piper Sandler Downgrades Collegium Pharmaceutical (COLL)
Fintel reports that on May 10, 2024, Piper Sandler downgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from Overweight to Neutral.

Lake Street Downgrades Vista Outdoor (VSTO)
Fintel reports that on May 10, 2024, Lake Street downgraded their outlook for Vista Outdoor (NYSE:VSTO) from Buy to Hold.